Krystal Biotech Inc
F:4KB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Krystal Biotech Inc
F:4KB
|
US |
|
S
|
Snap-On Inc
LSE:0L7G
|
US |
|
Telefonaktiebolaget LM Ericsson
LSE:0IID
|
SE |
Krystal Biotech Inc
Krystal Biotech is a biotechnology company that develops gene therapies for rare diseases, especially inherited skin disorders. Its main product is a topical gene therapy designed to help patients with dystrophic epidermolysis bullosa, a serious condition that makes the skin extremely fragile. The company also works on additional gene therapy programs that use the same core technology. The company sells prescription medicines to hospitals, doctors, and specialty pharmacies, and it earns money mainly from product sales as its therapies are approved and used in patients. In earlier stages, it also funds itself through research partnerships and development work tied to its drug pipeline. Because this is a drug company, a big part of its value comes from turning scientific research into approved treatments that can be manufactured and sold. What makes Krystal Biotech different is its focus on local, repeatable gene delivery rather than one-size-fits-all medicine. Its approach is designed for diseases where treating the affected tissue directly can matter more than sending a therapy throughout the whole body. That gives it a niche role in the rare-disease drug market, where patients, doctors, and regulators look for treatments that can address severe unmet medical needs.
Krystal Biotech is a biotechnology company that develops gene therapies for rare diseases, especially inherited skin disorders. Its main product is a topical gene therapy designed to help patients with dystrophic epidermolysis bullosa, a serious condition that makes the skin extremely fragile. The company also works on additional gene therapy programs that use the same core technology.
The company sells prescription medicines to hospitals, doctors, and specialty pharmacies, and it earns money mainly from product sales as its therapies are approved and used in patients. In earlier stages, it also funds itself through research partnerships and development work tied to its drug pipeline. Because this is a drug company, a big part of its value comes from turning scientific research into approved treatments that can be manufactured and sold.
What makes Krystal Biotech different is its focus on local, repeatable gene delivery rather than one-size-fits-all medicine. Its approach is designed for diseases where treating the affected tissue directly can matter more than sending a therapy throughout the whole body. That gives it a niche role in the rare-disease drug market, where patients, doctors, and regulators look for treatments that can address severe unmet medical needs.
Revenue: Krystal Biotech reported first-quarter global VYJUVEK net revenue of $116.4 million, up 9% sequentially and 32% year over year, with gross margin holding at 95%.
U.S. Demand: U.S. revenue was $87.5 million, but management said quarter-to-quarter swings can be noisy because of insurance switchovers and the start-stop treatment pattern they are now seeing more clearly.
International Launch: Europe and Japan contributed $28.9 million of revenue, and management sounded increasingly confident about the ex-U.S. rollout, with Italy and Spain next on the list if reimbursement talks go well.
Pipeline Milestones: The company said it is headed toward multiple data readouts this year, including two registrational readouts in the eye and early repeat-dose data for CF and Hailey-Hailey programs.
Balance Sheet: Cash and investments are now above $1 billion, and management said the company is not looking to buy or license assets right now while it remains in growth mode.
Guidance: Full-year 2026 non-GAAP R&D and SG&A expense guidance was left unchanged at approximately $175 million to $195 million.
